CoChat
Sign Up
Cited by 245

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Aldara activates TLR7-independent immune defence

Walter, Anne, Schäfer, Matthias, Cecconi, Virginia, Matter, Claudia, Urosevic-Maiwald, Mirjana, Belloni, Benedetta, Schönewolf, Nicola, Dummer, Reinhard, Bloch, Wilhelm, Werner, Sabine, Beer, Hans-Dietmar, Knuth, Alexander, van den Broek, Maries·2013·Nature Communications
DOI 10.1038/ncomms2566
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms2566

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aldara vehicle cream contains isostearic acid, which can trigger low-grade innate immune activation, including IL-1 release.

    “It has been reported that Aldara vehicle cream contains isostearic acid, which has been reported to trigger low-grade innate immune activation, including IL-1 release38,39.”

    From Macrophage INSIG1 deficiency drives psoriasiform dermatitis via the SREBP2-STAT1 axis (2026) · cites this paper as [38]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. Lacarrubba, F., Nasca, M. R. & Micali, G. Advances in the use of topical imiquimod to treat dermatologic disorders. Ther. Clin. Risk Manage. 4, 87–97 (2008) . · DOI
  2. Navi, D. & Huntley, A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol. J. 10, 4 (2004) .
  3. Oldfield, V., Keating, G. M. & Perry, C. M. Imiquimod: in superficial basal cell carcinoma. Am. J. Clin. Dermatol. 6, 195–200 discussion 201-2 (2005) . · DOI
  4. Dummer, R. et al. Imiquimod in basal cell carcinoma: how does it work? Br. J. Dermatol. 149, (Suppl 66): 57–58 (2003) . · DOI
  5. Urosevic, M. et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch. Dermatol. 139, 1325–1332 (2003) . · DOI
  6. Urosevic, M. et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J. Natl Cancer Inst. 97, 1143–1153 (2005) . · DOI
  7. Drobits, B. et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 122, 575–585 (2012) . · DOI
  8. Cai, Y. Pivotal role of dermal IL-17-producing gd T Cells in skin inflammation. Immunity 35, 596–610 (2011) . · DOI
  9. Huang, S. J. et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J. Invest. Dermatol. 129, 2676–2685 (2009) . · DOI
  10. Stary, G. et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exper Med 204, 1441–1451 (2007) . · DOI
  11. Suzuki, H. et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Invest. Dermatol. 114, 135–141 (2000) . · DOI
  12. Walter, A. et al. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin. Cancer Res. 16, 3562–3570 (2010) . · DOI
  13. Berman, B., Sullivan, T., De Araujo, T. & Nadji, M. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br. J. Dermatol. 149, (Suppl 66): 59–61 (2003) . · DOI
  14. Vidal, D., Matias-Guiu, X. & Alomar, A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br. J. Dermatol. 151, 656–662 (2004) . · DOI
  15. Schon, M. P. & Schon, M. Imiquimod: mode of action. Br. J. Dermatol. 157, (Suppl 2): 8–13 (2007) . · DOI
  16. Chuang, T. H. & Ulevitch, R. J. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur. Cytokine Netw. 11, 372–378 (2000) .
  17. Lebre, M. C. et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J. Invest. Dermatol. 127, 331–341 (2007) . · DOI
  18. Kono, T. et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. 13, 71–76 (1994) .
  19. Schon, M. P., Schon, M. & Klotz, K. N. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J. Invest. Dermatol. 126, 1338–1347 (2006) . · DOI
  20. Fanti, P. A., Dika, E., Vaccari, S., Miscial, C. & Varotti, C. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int. J. Dermatol. 45, 1464–1465 (2006) . · DOI
  21. Gilliet, M. et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140, 1490–1495 (2004) . · DOI
  22. van der Fits, L. et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836–5845 (2009) . · DOI
  23. Van Belle, A. B. et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J. Immunol. 188, 462–469 (2011) . · DOI
  24. Pantelyushin, S. et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122, 2252–2256 (2012) . · DOI
  25. Stanley, M. A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27, 571–577 (2002) . · DOI
  26. Rao, K. S., Babu, K. K. & Gupta, P. D. Keratins and skin disorders. Cell. Biol. Int. 20, 261–274 (1996) . · DOI
  27. Swiecki, M. et al. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J. Exp. Med. 208, 2367–2374 (2011) . · DOI
  28. Werner, S. & Smola, H. Paracrine regulation of keratinocyte proliferation and differentiation. Trends Cell Biol. 11, 143–146 (2001) . · DOI
  29. Werner, S., Krieg, T. & Smola, H. Keratinocyte-fibroblast interactions in wound healing. J. Invest. Dermatol. 127, 998–1008 (2007) . · DOI
  30. Adachi, O. et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143–150 (1998) . · DOI
  31. Pinkus, H. & Mehregan, A. H. The primary histologic lesion of seborrheic dermatitis and psoriasis. J. Invest. Dermatol. 46, 109–116 (1966) . · DOI
  32. Schon, M., Denzer, D., Kubitza, R. C., Ruzicka, T. & Schon, M. P. Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J. Invest. Dermatol. 114, 976–983 (2000) . · DOI
  33. Gebhardt, C., Nemeth, J., Angel, P. & Hess, J. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 72, 1622–1631 (2006) . · DOI · Paper page
  34. Frevert, C. W., Huang, S., Danaee, H., Paulauskis, J. D. & Kobzik, L. Functional characterization of the rat chemokine KC and its importance in neutrophil recruitment in a rat model of pulmonary inflammation. J. Immunol. 154, 335–344 (1995) . · DOI
  35. Sanos, S. L. et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat. Immunol. 10, 83–91 (2009) . · DOI
  36. Sims, J. E. & Smith, D. E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10, 89–102 (2010) . · DOI
  37. Kanneganti, T. D. et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440, 233–236 (2006) . · DOI
  38. Feldmeyer, L., Werner, S., French, L. E. & Beer, H. D. Interleukin-1, inflammasomes and the skin. Eur. J. Cell Biol. 89, 638–644 (2010) . · DOI
  39. Salcedo, R. et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 207, 1625–1636 (2010) . · DOI · Paper page
  40. Miao, E. A., Rajan, J. V. & Aderem, A. Caspase-1-induced pyroptotic cell death. Immunol. Rev. 243, 206–214 (2011) . · DOI
  41. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188 (2011) . · DOI · Paper page
  42. Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408–415 (2011) . · DOI · Paper page
  43. Keller, M., Ruegg, A., Werner, S. & Beer, H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818–831 (2008) . · DOI
  44. Brauchle, M., Angermeyer, K., Hubner, G. & Werner, S. Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts. Oncogene 9, 3199–3204 (1994) .
  45. Szabowski, A. et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 103, 745–755 (2000) . · DOI
  46. Takematsu, H. & Tagami, H. Granulocyte-macrophage colony-stimulating factor in psoriasis. Dermatologica 181, 16–20 (1990) . · DOI
  47. Beutner, K. R. et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J. Am. Acad. Dermatol. 41, 1002–1007 (1999) . · DOI
  48. van den Broek, M. F., Muller, U., Huang, S., Zinkernagel, R. M. & Aguet, M. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148, 5–18 (1995) . · DOI
  49. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196–200 (2002) . · DOI
  50. Hoshino, K. et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. 162, 5041–5044 (1999) . · DOI
  51. Eberl, G. et al. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 5, 64–73 (2004) . · DOI

Cited by

Sorted by citations

Metadata

Authors
Walter, A., Schäfer, M., Cecconi, V., Matter, C., Urosevic-Maiwald, M., Belloni, B., Schönewolf, N., Dummer, R., Bloch, W., Werner, S., Beer, H.-D., Knuth, A., & van den Broek, M.
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2013-03-05
Volume
4
Issue
1
ISSN
2041-1723
DOI
10.1038/ncomms2566
Cited by
245
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review